(S)-2-Amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one 2,2,2-trifluoroacetate

We are (S)-2-Amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one 2,2,2-trifluoroacetate CAS:247068-85-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(S)-2-Amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one 2,2,2-trifluoroacetate
CAS.NO:247068-85-5
Synonyms:(S)-2-Amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one 2,2,2-trifluoroacetate
(2S)-4-Methyl-1-[(2R)-2-methyl-2-oxiranyl]-1-oxo-2-pentanaminium trifluoroacetate
(2S)-2-Amino-4-methyl-1-[(2R)-2-methyl-2-oxiranyl]-1-pentanone trifluoroacetate
 
Physical and Chemical Properties:
Molecular Formula C11H18F3NO4
Molecular Weight 285.260
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Carfilzomib(CAS:868540-17-4).

(S)-2-Amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one 2,2,2-trifluoroacetate


Related News: The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.Ácido (10-fenilantracen-9-il) borónico CAS:334658-75-2 “Inceptua Medicines Access is delighted to be selected as Onconova’s partner for the Pre-approval Access Program for rigosertib.N- (terc-butoxicarbonil) piperidin-2-ona CAS:85908-96-9 “Inceptua Medicines Access is delighted to be selected as Onconova’s partner for the Pre-approval Access Program for rigosertib.5-fluoro-2-hidroxipiridina CAS:51173-05-8 “Inceptua Medicines Access is delighted to be selected as Onconova’s partner for the Pre-approval Access Program for rigosertib.In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.

Related Products
Product Name
4-Bromotetraphenylsilane Cas:18737-40-1 View Details
2-Bromoanisole View Details
diisononyl phthalate Cas:68515-48-0 View Details
ACETANILIDE Cas:103-84-4 manufacturer sodium dichloroisocyanurate Cas:2893-78-9 manufacturer 9-Bromoanthracene manufacturer Adenosine 5′-triphosphate Disodium Salt Hydrate Cas:34369-07-8 manufacturer Triphenylantimony Cas:603-36-1 manufacturer